PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab for Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First Line Chemotherapy

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and safety of PD-1 immune checkpoint inhibitor combined with bevacizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma after failure of first-line chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: XIANG YANQUN
• Treatments: Bevacizumab; Immune Checkpoint Inhibitors

Criteria

Inclusion Criteria:

• Patients diagnosed with metastatic or recurrent nasopharyngeal carcinoma are not suitable for radical local treatment.

• Previous failure of first-line platinum-containing chemotherapy (single drug or combination).

• Previously diagnosed WHO classification type II or III by histological pathology.

• At least one measurable lesion (according to RECIST1.1).

• Age between 18 and 70.

• Eastern Cooperative Oncology Group (ECOG) 0-1, and life expectation at least 3 months.

• Enough blood test.

• Participate voluntarily and sign the informed consent.

Exclusion Criteria:

• Previously diagnosed WHO classification type I by histological pathology.

• Previous use of bevacizumab.

• Previous use of sorafenib, apatinib, sunitinib, amlotinib and other small molecule --vascular targeting drugs.

• Previous treatment with PD-1 mmune checkpoint inhibitor.

• Necrotizing lesions were found within the first 4 weeks, or the risk of massive bleeding.

• A history of interstitial pneumonia or other autoimmune diseases.

• Sever infection.

• Sever heart disease.

• HIV infection.

• Allogeneic organ transplantation

• Malignancy other than nasopharyngeal carcinoma.

• Pregnancy or breast feeding.

• Received other test drugs.